Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL. van Gelder M, Tournilhac O, Te Raa D, Visser HPJ, et al. Ann Oncol 2021;32:1442-1443.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

van Gelder M, Tournilhac O, Te Raa D, Visser HPJ, et al. Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL. Ann Oncol 2021;32:1442-1443.
PMID: 34428511